Tibet AIM Pharm. Inc.

002826

CNE100002C39

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
7.78 ^CNY	-0.38%		-0.51%	-34.46%

03/07	Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	CI
25/04	Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tibet AIM Pharm. Inc.(SZSE:002826) added to Shenzhen Stock Exchange A Share Index

January 11, 2017 at 10:30 am IST

Tibet AIM Pharm Inc. has been added to Shenzhen Stock Exchange A Share Index.

Latest news about Tibet AIM Pharm. Inc.

Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	04/07	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	02/04	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	02/01	CI
Tibet AIM Pharm. Inc. announces an Equity Buyback for CNY 100 million worth of its shares.	29/23/29	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Tibet AIM Pharm. Inc. authorizes a Buyback Plan.	26/23/26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Tibet Aim Pharm Chairman Resigns; Successor Named	13/23/13	MT
Tibet Aim Pharm Unit to Buy 21% Stake in US Medtech Firm Pier 88 Health for $6 Million	13/23/13	MT
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	24/22/24	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	08/22/08	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	24/21/24	CI
Tibet AIM Pharm. Inc. Approves the Election of Non-Independent Directors, Independent Directors and Non-Employee Supervisors	15/21/15	CI
Tibet Aim Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	25/21/25	CI
Tibet AIM Pharm. Inc. agreed to acquire 51% stake in Inner Mongolia Bositai Enterprise Management Service Co., Ltd. for CNY 30.6 million.	14/21/14	CI
Tibet AIM Pharm. Inc. cancelled the transaction announced on April 6, 2021	13/21/13	CI
Tibet Aim Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	27/21/27	CI
Tibet AIM Pharm. Inc. announced that it expects to receive CNY 349.999994 million in funding	06/21/06	CI
Tibet Aim Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	28/20/28	CI
Tibet Aim Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	25/20/25	CI

TIBET AIM PHARM INC is a China-based company principally engaged in the research, design, manufacture and distribution of chemical drugs and Chinese patent medicine. The Companyâs products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

16/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIBET AIM PHARM. INC.	-34.46%	20Cr
ELI LILLY AND COMPANY	+61.53%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	16TCr